EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps

Mu Xian iD, Bing Yan, Xicheng Song, Jianjun Chen, Jun Tang, Yan Jiang, Lijia Wan, Wen Liu, Jinmei Xue, Zhiwei Cao, Yafeng Yu, Xiangli Yang und 34 weitere

Allergy · 2025

DOI: 10.1111/all.16519 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Allergy, 2025. Verfasst von Mu Xian und 45 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Biological Products, Biological Therapy, Nasal Polyps, Rhinitis. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Beijing Municipal Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Emerging biologics that selectively target key cytokines present a promising therapeutic alternative for patients suffering from severe, uncontrollable chronic rhinosinusitis with nasal polyps (CRSwNP). Despite the limited availability of registered biologics for CRSwNP treatment in China, the country is experiencing rapid development in this field. It is imperative to standardize the application of biologic agents in CRSwNP management in preparation for their future integration into the CRSwNP care pathway. The Rhinology Group, Chinese Society of Otorhinolaryngology‐Head and Neck Surgery; the Rhinology Group, Chinese Medical Doctor Association of Otorhinolaryngology‐Head and Neck Surgery; and the Nasal and Ocular Allergy Group, Chinese Society of Allergy have convened an expert panel consisting of principal investigators experienced in clinical trials of biologic treatment for CRSwNP. This expert panel was assembled to discuss the application of biologic agents in patients with CRSwNP in China. Additionally, the latest findings on the pathogenesis of CRSwNP, mechanisms of biologic agents, and efficacy and safety of biologic treatment in patients with CRSwNP were reviewed, with a special emphasis on research evidence from China. The expert panel reached a consensus on several critical issues, including criteria for the prescription, treatment course, and efficacy evaluation from a Chinese perspective. This position paper aims to guide Chinese physicians in the use of biologic agents for patients with CRSwNP. As our experience with biologic treatment continues to grow, this position paper will be further updated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsBiological TherapyNasal PolypsRhinitisSinusitisHumansChinaChronic DiseaseDisease ManagementRhinosinusitisTreatment Outcome

Stichwörter der Autor:innen

Chinabiologicschronic rhinosinusitis with nasal polypsmonoclonal antibodytreatment

Substanzen

Biological Products

Autor:innen und Institutionen

  • Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.
  • Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of New Medicine and Diagnostic Technology Research for Nasal Disease, Key Laboratory of Otolaryngology Head and Neck S…
  • Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.
  • Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.
  • Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Otolaryngology Department, The First People's Hospital, Foshan, Guangdong, China.

ORCID-Profile: Mu Xian, Yu Xu, Yucheng Yang, Jing Ye, Guolin Tan, Xiaowen Zhang, Huabin Li, Zheng Liu, Dongdong Zhu, Lei Cheng, Chengshuo Wang, Luo Zhang

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Beijing Municipal Science and Technology Project
  • Capital's Funds for Health Improvement and Research
  • Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes, Beijing Municipal Health Commission
  • National Key Research and Development Program of China

Zitieren

APA

Xian, M., Yan, B., Song, X., Chen, J., Tang, J., Jiang, Y., Wan, L., Liu, W., Xue, J., Cao, Z., Yu, Y., Yang, X., Shi, L., Wang, G., Xu, Y., Yang, Y., Ye, J., Jiang, L., Quan, F., …, & Zhang, L. (2025). Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps. Allergy. https://doi.org/10.1111/all.16519

Vancouver

Xian M, Yan B, Song X, Chen J, Tang J, Jiang Y, et al. Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps. Allergy. 2025. doi:10.1111/all.16519

BibTeX
@article{Xian2025,
  author = {Xian, Mu and Yan, Bing and Song, Xicheng and Chen, Jianjun and Tang, Jun and Jiang, Yan and Wan, Lijia and Liu, Wen and Xue, Jinmei and Cao, Zhiwei and Yu, Yafeng and Yang, Xiangli and Shi, Li and Wang, Guangke and Xu, Yu and Yang, Yucheng and Ye, Jing and Jiang, Luyun and Quan, Fang and Tan, Guolin and Liu, Feng and Xu, Zhendong and Zhang, Xiaowen and Li, Jiping and Su, Lizhong and Yang, Yi and Fan, Jiangang and He, Gang and Zhu, Li and Wang, Xiangdong and Wang, Ming and Shen, Shen and Li, Jian and Li, Huabin and Wei, Xin and Yu, Hongmeng and Liu, Zheng and Ma, Ruixia and Liu, Huanhai and Liu, Jianfeng and Lv, Wei and Yang, Qintai and Zhu, Dongdong and Cheng, Lei and Wang, Chengshuo and Zhang, Luo},
  title = {Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16519}
}
Kostenlos starten →